“There is currently no medicine approved for hypothalamic obesity, a rare disease characterized by intractable weight gain and complicated by uncontrollable hunger. Feldt-Rasmussen share the data from our positive Phase 2 trial of Tesomet for the treatment of hypothalamic obesity with the medical community through an oral presentation at such a prestigious medical conference as ENDO,” said Rudolf Baumgartner, M.D., Chief Medical Officer and Head of Clinical Development at Saniona. Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that data from its Phase 2 clinical trial of Tesomet for hypothalamic obesity (HO) will be presented at the Endocrine Society’s 2021 Annual Meeting (ENDO 2021), which is being held virtually March 20-23, 2021.ĮNDO is the leading meeting for endocrinology research and clinical care worldwide. Saniona’s Tesomet data will be featured in a live oral presentation titled, “Weight Loss, Improved Body Composition and Fat Distribution by Tesomet in Acquired Hypothalamic Obesity,” presented by Professor Ulla Feldt-Rasmussen, M.D., DMSc., Department of Medical Endocrinology and Metabolism, Rigshospitalet Copenhagen University Hospital, and Principal Investigator on the Phase 2 study. The presentation will be given on March 23 at 2:15 pm EDT as part of session OR02: What’s New in Weight Management Through the Lifespan? The data are embargoed until the time of presentation.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |